<DOC>
	<DOCNO>NCT02058459</DOCNO>
	<brief_summary>The purpose study evaluate safety Targeted Lung Denervation ( TLD ) patient suffer moderate severe COPD . It hypothesize TLD similar safety profile improve physiological functional outcome sham-control .</brief_summary>
	<brief_title>Targeted Lung Denervation Patients With Moderate Severe COPD</brief_title>
	<detailed_description>A prospective , sequential two phase multicenter , randomize double-blind , safety , &amp; feasibility study . The goal AIRFLOW-1 compare two energy dos select optimal energy dose utilized AIRFLOW-2 . The goal AIRFLOW-2 compare optimal energy dose sham control . All subject follow minimum 3 year .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Diagnosis COPD 30 % ≤ FEV1 &lt; 60 % FEV1/FVC &lt; 70 % ( postbronchodilator ) ; Patient ≥ 40 ≤ 75 year age time consent ; The patient child bear potential negative pregnancy test ( serum urine ) , applicable ; Smoking history least 10 pack year ; Nonsmoking minimum 2 month prior consent agrees continue smoke duration study ; Participated pulmonary rehabilitation program engage regular physical activity professional supervision past 12 month ; Has le 6 week follow resolution COPD exacerbation active low respiratory infection ( eg . pneumonia ) ; History recurrent respiratory infection and/or COPD exacerbation ( 2 hospitalization within 1 year enrollment ) ; Prior lung chest procedure ( eg . lung transplant , LVRS , BLVR , lung implant , metal stent , valve , coil , median sternotomy , bullectomy , segmentectomy , lobectomy ) ; Documented history asthma diagnose onset &lt; 30 year age , cystic fibrosis , paradoxical vocal cord motion , ChurgStrauss syndrome , allergic bronchopulmonary aspergillosis , severe interstitial lung disease active tuberculosis ; Pulmonary nodule require followup intervention unless proven benign ; Daily use &gt; 10 mg prednisone equivalent time enrollment ;</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chronic obstructive pulmonary disease , target lung denervation , intervention , device , safety , lung function , Holaira</keyword>
</DOC>